A Circulating microRNA Signature Predicts Age-Based Development of Lymphoma

• Published in: PloS one Vol. 12; no. 1; p. e0170521
• Main Authors: Beheshti, Afshin, Vanderburg, Charles, McDonald, J Tyson, Ramkumar, Charusheila, Kadungure, Tatenda, Zhang, Hong, Gartenhaus, Ronald B, Evens, Andrew M
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 20.01.2017; Public Library of Science (PLoS)
• Subjects: Age; Age Factors; Analysis; Animal models; Animals; B-cell lymphoma; Biology; Biology and life sciences; Blood circulation; Blotting, Western; Bone marrow; Bone Marrow - metabolism; Cancer; Carcinogens; Development and progression; Epidemiology; Etiology; Gene expression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hematology; Humans; Lymphocytes B; Lymphoma; Lymphoma, Large B-Cell, Diffuse - etiology; Lymphomas; Medical innovations; Medical prognosis; Medical research; Medical schools; Medicine and Health Sciences; Mice; Mice, Inbred C57BL; MicroRNA; MicroRNAs; MicroRNAs - genetics; MicroRNAs - physiology; miRNA; Myc protein; Oncology; Polymerase Chain Reaction; Research and Analysis Methods; Ribonucleic acid; Risk assessment; RNA; Signaling; Signatures; Spleen; Spleen - metabolism; Tumors; Ubiquitin-Protein Ligases - deficiency
• DOI: 10.1371/journal.pone.0170521
• ISSN: 1932-6203

Extensive epidemiological data have demonstrated an exponential rise in the incidence of non-Hodgkin lymphoma (NHL) that is associated with increasing age. The molecular etiology of this remains largely unknown, which impacts the effectiveness of treatment for patients. We proposed that age-dependent circulating microRNA (miRNA) signatures in the host influence diffuse large B cell lymphoma (DLBCL) development. Our objective was to examine tumor development in an age-based DLBCL system using an inventive systems biology approach. We harnessed a novel murine model of spontaneous DLBCL initiation (Smurf2-deficient) at two age groups: 3 and 15 months old. All Smurf2-deficient mice develop visible DLBCL tumor starting at 15 months of age. Total miRNA was isolated from serum, bone marrow and spleen and were collected for all age groups for Smurf2-deficient mice and age-matched wild-type C57BL/6 mice. Using systems biology techniques, we identified a list of 10 circulating miRNAs being regulated in both the spleen and bone marrow that were present in DLBCL forming mice starting at 3 months of age that were not present in the control mice. Furthermore, this miRNA signature was found to occur circulating in the blood and it strongly impacted JUN and MYC oncogenic signaling. In addition, quantification of the miRNA signature was performed via Droplet Digital PCR technology. It was discovered that a key miRNA signature circulates throughout a host prior to the formation of a tumor starting at 3 months old, which becomes further modulated by age and yielded calculation of a 'carcinogenic risk score'. This novel age-based circulating miRNA signature may potentially be leveraged as a DLBCL risk profile at a young age to predict future lymphoma development or disease progression as well as for potential innovative miRNA-based targeted therapeutic strategies in lymphoma.